Shuji Kanmura

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 86 citations · Full text

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression

Nao Nishikoba, Kotaro Kumagai, Shuji Kanmura et al. · Frontiers in Immunology · 2020 · 75 citations · Full text

Glycoprotein Nonmetastatic Melanoma B (Gpnmb)-Positive Macrophages Contribute to the Balance between Fibrosis and Fibrolysis during the Repair of Acute Liver Injury in Mice

Kotaro Kumagai, Kazuaki Tabu, Fumisato Sasaki et al. · PLoS ONE · 2015 · 67 citations · Full text

Transgenic expression of human neutrophil peptide‐1 enhances hepatic fibrosis in mice fed a choline‐deficient, L‐amino acid–defined diet

Rie Ibusuki, Hirofumi Uto, Shiho Arima et al. · Liver International · 2013 · 61 citations